Renaissance Technologies LLC decreased its holdings in shares of Nutex Health Inc. (NASDAQ:NUTX - Free Report) by 63.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,903 shares of the company's stock after selling 100,497 shares during the period. Renaissance Technologies LLC owned about 1.14% of Nutex Health worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, One Plus One Wealth Management LLC lifted its holdings in Nutex Health by 2,017.5% in the 1st quarter. One Plus One Wealth Management LLC now owns 5,293,720 shares of the company's stock valued at $508,000 after purchasing an additional 5,043,720 shares in the last quarter. 5.32% of the stock is currently owned by hedge funds and other institutional investors.
Nutex Health Trading Up 11.2 %
Shares of NASDAQ NUTX traded up $2.17 during trading on Tuesday, hitting $21.47. 79,963 shares of the company were exchanged, compared to its average volume of 39,754. Nutex Health Inc. has a 12-month low of $4.16 and a 12-month high of $45.00. The company has a debt-to-equity ratio of 3.04, a quick ratio of 1.55 and a current ratio of 1.59. The company has a fifty day moving average price of $19.65 and a 200-day moving average price of $11.49. The firm has a market capitalization of $106.75 million, a PE ratio of -1.93 and a beta of 0.10.
Nutex Health (NASDAQ:NUTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.22. Nutex Health had a negative return on equity of 43.79% and a negative net margin of 13.73%. The business had revenue of $76.08 million for the quarter.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on NUTX shares. Maxim Group started coverage on Nutex Health in a report on Wednesday, September 18th. They issued a "buy" rating and a $45.00 price objective on the stock. Benchmark raised their price objective on Nutex Health from $30.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, August 21st.
Get Our Latest Stock Report on NUTX
Insider Transactions at Nutex Health
In other Nutex Health news, CFO Jon Christian Bates acquired 1,350 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average cost of $21.46 per share, with a total value of $28,971.00. Following the transaction, the chief financial officer now owns 2,277 shares of the company's stock, valued at $48,864.42. This trade represents a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 38.52% of the company's stock.
About Nutex Health
(
Free Report)
Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.
Featured Articles
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
